💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Clopidogrel Bisulfate

CHEMBL1083385 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
419.9 g/mol
LogP
—
Phase
4

The bisulfate salt form of clopidogrel, the standard oral antiplatelet preparation used to prevent dangerous blood clots in arteries. This prodrug must be converted by liver enzymes to its active form before it can inhibit platelet aggregation.

Молекулярная масса

419,9000 g/mol

TPSA

141,00 Ų

Терапевтические области

Pancreatic Cancer Cardiovascular Disease Age-Related Macular Degeneration Pain Management Chronic Obstructive Pulmonary Disease Parkinson's Disease Epilepsy Migraine Systemic Lupus Erythematosus Multiple Sclerosis Chronic Kidney Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Hyperlipidemia Type 2 Diabetes Hypertension Major Depressive Disorder Gout Chronic Pain HIV/AIDS Heart Failure Atrial Fibrillation

Механизм действия

Irreversibly blocks P2Y12 ADP receptor on platelets.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Irreversibly blocks P2Y12 ADP receptor on platelets.

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1.O=S(=O)(O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C16H16ClNO2S.H2O4S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;1-5(2,3)4/h2-5,7,9,15H,6,8,10H2,1H3;(H2,1,2,3,4)/t15-;/m0./s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C16H18ClNO6S2

                    

                    
                    

                        
HBD / HBA

                        
2 / 8

                    

                    
                    

                        
Вращаемые Связи

                        
4

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
26

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
The bisulfate salt form of clopidogrel, the standard oral antiplatelet preparation used to prevent dangerous blood clots in arteries. This prodrug must be converted by liver enzymes to its active form before it can inhibit platelet aggregation.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Irreversibly blocks P2Y12 ADP receptor on platelets.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Clopidogrel Bisulfate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1083385.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 115366.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.